Lindsay A. Rosenwald MD - 28 May 2025 Form 4 Insider Report for Checkpoint Therapeutics, Inc. (CKPT)

Role: Director
Signature: /s/ James F. Oliviero, Attorney-in-Fact
Issuer symbol: CKPT
Transactions as of: 28 May 2025
Net transactions value: +$64,500
Form type: 4
Filing time: 30 May 2025, 11:19:22 UTC
Previous filing: 03 Jan 2025
Next filing: 07 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
ROSENWALD LINDSAY A MD	Director	95 SAWYER ROAD, SUITE 110, WALTHAM	/s/ James F. Oliviero, Attorney-in-Fact	30 May 2025	0000941841

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CKPT	COMMON STOCK	Award	$0	+12,195	+8.4%	$0.000000	157,007	28 May 2025	Direct	F1
transaction	CKPT	COMMON STOCK	Award	$64,500	+50,000	+32%	$1.29	207,007	29 May 2025	Direct
transaction	CKPT	COMMON STOCK	Disposition pursuant to a tender of shares in a change of control transaction		-207,007	-100%		0	30 May 2025	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Lindsay A. Rosenwald MD is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Rosenwald's continued service on the board.
F2	Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency.

Content

Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Rosenwald's continued service on the board.

Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency.